ISRCTN08592155已完成4 期
Switching from efavirenz/tenofovir/emtricitabine (TDF/FTC/EFV) to abacavir/lamivudine/maraviroc (ABC/3TC/MVC) to assess antiretroviral activity in cerebrospinal fluid: a prospective one-arm pilot study
Institute of Biomedical Investigations of Bellvitge [Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)] (Spain)0 个研究点目标入组 15 人开始时间: 2011年4月18日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
- 2015 results in https://www.ncbi.nlm.nih.gov/pubmed/25721471 (added 21/01/2019)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Human immunodeficiency virus positive (HIV+)
- •2. Adults aged over 18 years
- •3. HLA-B*57:01:01 negative
- •4. On TDF/FTC/EFV treatment for at least 24 weeks and undetectable HIV viral load in the last 24 weeks
- •5. Neurocognitive impairment
- •6. CCR5+ (pro-viral deoxyribonucleic acid [DNA])
- •7. Signed informed consent
排除标准
- •1. Alanine aminotransferase (ALT) greater than 5 fold upper normal limit
- •2. Renal impairment (creatinine clearance [Cl cr] less than 50 ml/min)
- •3. Haemoglobin less than 9 g/dl
- •4. Neutropenia (PMN) less than 1000/ml
- •5. Platelets less than 30,000/mm3
- •6. Opportunistic infection, cancer and /or any disease which could alter blood brain barrier permeability (meningitis, cancer, etc.)
- •7. Neuro-psychiatric disease (previous or current)
- •8. Illicit drugs use
研究者
相似试验
进行中（未招募）
1 期
Substitution current ARV therapy by BIKTARVY in hiv infected patients over 65 years oldHIV-1-infected patientAge > 65 years oldPlasma HIV RNA = 50 copies/mL for = 6 months: one blip between 50 et 200 cp/ml is allowed in the last 6 months before screening.Currently receiving an antiretroviral regimen containing a booster, ritonavir or cobicistat No resistance mutation to integrase inhibitors on cumulative HIV RNA genotype. Patient enrolled in or a beneficiary of a Social Security program Informed consent form signedEUCTR2019-002843-81-FRIMEA50
已完成
不适用
Switching from Lopinavir/Ritonavir Plus Tenofovir and Emtricitabine (or Lamivudine) to Darunavir (Prezista) and Raltegravir to Evaluate Renal FunctioHIV infections, AIDS, HIV-1JPRN-UMIN000005116AIDS Clinical Center at National Center for Global Health and Medicine54
进行中（未招募）
4 期
Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 InfectionHIV-1-infectionNCT05122754Shanghai Public Health Clinical Center150
已完成
3 期
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDFHIV-1 InfectionNCT02121795Gilead Sciences668
招募中
不适用
Efficacy of entecavir-to-tenofovir switching treatment to attain a drug-free state in chronic hepatitis B: a randomized controlled trialchronic hepatitis BJPRN-UMIN000021793Department of Hepatology, Osaka Metropolitan University90